Our laboratories are working on the basic research level.

The finding suggests that could drugs that inhibit the release of renin by local mast cells to protect patients from heart arrhythmias. Our laboratories are working on the basic research level, the research in the pharmaceutical industry would have to move the clinical setting, said Silver. But it looks promising. University too have implications for the treatment of non – acute diseases such as heart failure.

The Agency also sends scholars for undergraduate, Doctoral and post – doctoral training in the best universities, a reflection of the high priority A* STAR places on cultivating the next generation of young scientists.. We are trying the infocomm and media value creator that keeps Singapore being ahead. Web site:Agency for Science, Technology and Research :A* STAR is Singapore’s lead agency for the promotion of world-class scientific research and talent for a vibrant knowledge-based Singapore.ChemoCentryx leading substance, Traficet-EN, in a specific CCR9 antagonist, is in Phase II / III multi-national clinical trial, called PROTECT-1,. For patients with moderate to heavy Crohn CCX025 also an CCR9 antagonist, is in a Phase I clinical trial. Additional clinical program comprise the development of CCX140 , which to CCR2 receptor, currently being into stage I clinical development and is to for the further development by diseases such as type 2 diabetes mellitus , multiple sclerosis and vascular restenosis and CCX354 a CCR1 antagonists period I treat clinical trials that inflammatory diseases inflammatory diseases as rheumatoid arthritis.

Traficet-EN is an oral small molecule controlling the inappropriate the immune system response underlying inflammatory bowel diseases by the blocking of CCR9 chemokine. Targeted the CCR9 chemokine receptor represents a novel approach for treatment of Crohn’s disease and other inflammatory illnesses of gastrointestinal system. DDW 2009 is on 30 Scheduled for May – 4 June 2009 at McCormick Place in Chicago, Illinois.. ChemoCentryx announced today that the data from the firm PROTECT-1 phase II / III trial of Traficet-EN for patients with moderate to severe Crohn will be introduced in an oral session at the upcoming 2,009 the Digestive Disease Week are session.

Other Posts From "potency":

Related Posts